VX-984

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C23H23N7O
Molecular Weight	415.4873
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[2H]C1=NC(C)=NC([2H])=C1C2=NC=NC(NC[C@@H](C)C3=C4N=CC=C(C(=O)NC)C4=CC=C3)=C2

InChI

InChIKey=PEACIOGDEQRHFA-KIYKJNLWSA-N

InChI=1S/C23H23N7O/c1-14(17-5-4-6-18-19(23(31)24-3)7-8-25-22(17)18)10-28-21-9-20(29-13-30-21)16-11-26-15(2)27-12-16/h4-9,11-14H,10H2,1-3H3,(H,24,31)(H,28,29,30)/t14-/m1/s1/i11D,12D

HIDE SMILES / InChI

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
DNA-dependent protein kinase 11 Target ID: CHEMBL3142 Sources: https://www.ncbi.nlm.nih.gov/pubmed/29549168 \| https://www.ncbi.nlm.nih.gov/pubmed/28423228	Inhibitor 8297

PubMed

Title	Date	PubMed
The DNA-PK Inhibitor VX-984 Enhances the Radiosensitivity of Glioblastoma Cells Grown In Vitro and as Orthotopic Xenografts.	2018 Jun	29549168

Name

Type

Language

VX-984

Code

English

4-QUINOLINECARBOXAMIDE, N-METHYL-8-((1S)-1-METHYL-2-((2'-METHYL(4,5'-BIPYRIMIDIN)-6-YL-4',6'-D2)AMINO)ETHYL)-

Systematic Name

English

N-METHYL-8-((2S)-1-((6-(2-METHYL(2H2)PYRIMIDIN-5-YL)PYRIMIDIN-4-YL)AMINO)PROPAN-2-YL)QUINOLINE-4-CARBOXAMIDE

Common Name

English

M-9831

Code

English

Code System Code Type Description

CAS

1476074-39-1

Created by admin on Sat Dec 16 11:15:46 GMT 2023 , Edited by admin on Sat Dec 16 11:15:46 GMT 2023

PRIMARY

FDA UNII

0C33IBK195

Created by admin on Sat Dec 16 11:15:46 GMT 2023 , Edited by admin on Sat Dec 16 11:15:46 GMT 2023

PRIMARY

PUBCHEM

72188357

Created by admin on Sat Dec 16 11:15:46 GMT 2023 , Edited by admin on Sat Dec 16 11:15:46 GMT 2023

PRIMARY

NCI_THESAURUS

C129061

Created by admin on Sat Dec 16 11:15:46 GMT 2023 , Edited by admin on Sat Dec 16 11:15:46 GMT 2023

PRIMARY

ACTIVE MOIETY


					0C33IBK195

VX-984